Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: Expression of angiopoietin-2 represents an independent prognostic factor for overall survival

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1109-1117

  Loges, Sonja ^a   Heil, Gerhard ^a   Bruweleit, Melanie ^a   Schoder, Volker ^a   Butzal, Martin ^a   Fischer, Uta ^a   Gehling, Ursula M ^a   Schuch, Gunter ^a   Hossfeld, Dieter K ^a   Fiedler, Walter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CYTOKINE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CELL ISOLATION; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA ISOLATION; UNIVARIATE ANALYSIS; ACUTE DISEASE; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; MYELOID LEUKEMIA; NEOVASCULARIZATION (PATHOLOGY); SURVIVAL;

ACUTE DISEASE; ANGIOPOIETIN-1; ANGIOPOIETIN-2; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, TIE-2; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 20044371963     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.058     Document Type: Article

References (43)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31, 1995
2. Risau W: Mechanisms of angiogenesis. Nature 386:671-674, 1997
3. Fiedler W, Staib P, Kuse R, et al: Role of angiogenesis inhibitors in acute myeloid leukemia. Cancer J 7:S129-S133, 2001 (suppl 3)
4. Aigner A, Butscheid M, Kunkel P, et al: An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 92:510-517, 2001
5. Berger W, Setinek U, Mohr T, et al: Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 83:415-423, 1999
6. Strutz F, Zeisberg M, Renziehausen A, et al: TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). Kidney Int 59:579-592, 2001
7. Mustonen T, Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129:895-898, 1995
8. Davis S, Aldrich TH, Jones PF, et al: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169, 1996
9. Davis S, Yancopoulos GD: The angiopoietins: Yin and yang in angiogenesis. Curr Top Microbiol Immunol 237:173-185, 1999
10. Valenzuela DM, Griffiths JA, Rojas J, et al: Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A 96:1904-1909, 1999
11. Sato TN, Tozawa Y, Deutsch U, et al: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70-74, 1995
12. Korpelainen El, Alitalo K: Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 10:159-164, 1998
13. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997
14. Lobov IB, Brooks PC, Lang RA: From the cover: Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99:11205-11210, 2002
15. Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998, 1999
16. Visconti RP, Richardson CD, Sato TN: Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 99:8219-8224, 2002
17. Fiedler W, Graeven U, Ergun S, et al: Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89:1870-1875, 1997
18. Bellamy WT, Richter L, Frutiger Y, et al: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733, 1999
19. Aguayo A, Estey E, Kantarjian H, et al: Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94:3717-3721, 1999
20. Fiedler W, Graeven U, Ergun S, et al: Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 11:1234-1237, 1997
21. Dias S, Choy M, Alitalo K, et al: Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99:2179-2184, 2002
22. Muller A, Lange K, Gaiser T, et al: Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk Res 26:163-168, 2002
23. Watarai M, Miwa H, Shikami M, et al: Expression of endothelial cell-associated molecules in AML cells. Leukemia 16:112-119, 2002
24. Heil G, Krauter J, Raghavachar A, et al: Risk-adapted induction and consolidation therapy in adults with de novo AML aged
25. Rozen S, Skaletsky H: Primer3 on the WWW for general users and biologist programmers, in Krawetz S, Misener S (eds): Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ, Humana Press, 2000, pp 365-386
26. Tischer E, Mitchell R, Hartman T, et al: The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954, 1991
27. Huang YQ, Li JJ, Karpatkin S: Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood 95:1993-1999, 2000
28. Therneau T, Grambsch P, Fleming T: Martingale-based residuals for survival models. Biometrika 77:147-160, 1990
29. Grambsch PM: Goodness-of-fit and diagnostics for proportional hazards regression models. Cancer Treat Res 75:95-112, 1995
30. Aguayo A, Kantarjian H, Manshouri T, et al: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96:2240-2245, 2000
31. Albitar M: Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol 106:170-176, 2001
32. Lee JH, Koh JT, Shin BA, et al: Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer. Int J Oncol 18:355-361, 2001
33. Verstovsek S, Kantarjian H, Manshouri T, et al: Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 99:2265-2267, 2002
34. de Bont ES, Rosati S, Jacobs S, et al: Increased bone marrow vascularization in patients with acute myeloid leukaemia: A possible role for vascular endothelial growth factor. Br J Haematol 113:296-304, 2001
35. Kern W, Haferlach T, Schoch C, et al: Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 101:64-70, 2003
36. Liso V, Albano F, Pastore D, et al: Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica 85:1285-1290, 2000
37. Wheatley K, Burnett AK, Goldstone AH, et al: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69-79, 1999
38. Lin P, Polverini P, Dewhirst M, et al: Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100:2072-2078, 1997
39. Vajkoczy P, Farhadi M, Gaumann A, et al: Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 109:777-785, 2002
40. Holash J, Wiegand SJ, Yancopoulos GD: New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356-5362, 1999
41. Asahara T, Chen D, Takahashi T, et al: Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83:233-240, 1998
42. Sfiligoi C, de Luca A, Cascone I, et al: Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 103:466-474, 2003
43. Tanaka F, Ishikawa S, Yanagihara K, et al: Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62:7124-7129, 2002